RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:any one read le journal des affaires this week? Jack, most definitely but only for IV applications where the objective is to bring Pg levels up to normal levels in acquired deficiency patients. The subcutaneous apps like diabetic ulcers may have an additional step because the formulation is different. We definitely need clarity on all this. But one can see a snowball effect that will come with Pg approval. If favourable, I can see the market begin to start pricing these other apps of IV Pg if the FDA grants priority review and a relatively short PDUFA date.